Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NetraMark Holdings ( (TSE:AIAI) ) has provided an announcement.
NetraMark Holdings has entered a strategic research collaboration with Italy’s Fondazione per la Medicina Personalizzata to analyze data from the landmark ROME Phase II precision-oncology trial using its NetraAI platform. The initiative aims to identify clinically actionable patient subgroups and biomarker-anchored treatment patterns that differentiate tailored therapies from standard of care across key endpoints such as progression-free survival and response rates.
The collaboration is expected to generate long-term value by combining FMP’s extensive oncology datasets with NetraMark’s explainable AI, enhancing NetraAI’s disease-stratification capabilities and supporting future clinical trial design and biomarker development. For stakeholders, the partnership positions NetraMark more firmly in precision oncology analytics, potentially improving responder-enrichment strategies for future sponsors and informing prospective patient stratification in upcoming clinical studies.
More about NetraMark Holdings
NetraMark Holdings Inc. is an artificial intelligence company focused on applying AI-powered precision analytics to pharmaceutical clinical trials. Its proprietary NetraAI platform is designed to uncover clinically meaningful patient subpopulations and biomarker-driven treatment patterns, with a particular focus on improving trial design and precision-oncology strategies.
Average Trading Volume: 46,249
Technical Sentiment Signal: Hold
Current Market Cap: C$87.24M
For detailed information about AIAI stock, go to TipRanks’ Stock Analysis page.